APLS vs SO · rev $781.4M vs P/E 22, rev $29.55B
Apellis Pharmaceuticals Inc (APLS) versus Southern Company (SO) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Southern Company (SO) is a utilities - regulated electric company listed on US.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
Latest reported SO revenue for 2025-12-31 was $29.55B. Net income was $4.34B. Revenue was up 10.6% from 2024-12-31 to 2025-12-31. SO currently screens at market cap $101.55B and trailing P/E 22.1.
APLS currently screens at market cap $2.29B. SO currently screens at market cap $101.55B and trailing P/E 22.1.
Not investment advice. Open the APLS and SO stock pages for the full models.
Not investment advice.